TET2 and hematologic disorder: Loss of the ten-eleven translocation methylcytosine dioxygenase 2 (Tet2) gene, which is commonly mutated in hematological malignancies, dysregulates inflammatory pathways, including the interleukin-1 (IL-1) pathway [1–3].